For example, in cases of intraventricular thrombolytic therapy where a recombinant tissue plasminogen activator was used to treat intraventricular hemorrhage, patients incurred a 23% tract hemorrhage rate, due largely to the fact that 30% of catheters did not terminate in the desired location [19,20]. The gene discussed is PLAT; the disease is Intraventricular hemorrhage.